Global law firm Freshfields has advised Leerink Partners, Evercore ISI and Cantor as joint book-running managers and RBC Capital Markets as co-manager in connection with 4D Molecular Therapeutics’ $100 million underwritten offering of common stock and pre-funded warrants.

The offering includes 8,385,809 shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,128,949 shares of common stock. The shares of common stock are being sold at a price of $10.51 per share and the pre-funded warrants are being sold at a price of $10.5099 per pre-funded warrant, which represents the per share price for the common stock less the $0.0001 per share exercise price for each pre-funded warrant. The offering closed on November 7, 2025.

The Freshfields team was led by capital markets partners Phillip Stoup and Jacqueline Marino and includes senior associate Katherine Kim, associates Yunah Ko and Breandan Mchale, partner Vinita Kailasanath and associate Juliana Zhang on intellectual property matters and counsel Jay Cosel on tax matters.